Loading clinical trials...
Loading clinical trials...
This is a Post-Marketing Surveillance study of Abilify® tablets in accordance with Korean regulations on New Drug Re-examination (i.e. New Drug Re-examination Standards: KFDA Notification No. 2010-94 ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
NCT01418339 · Tourette's Disorder
NCT03661983 · Tourette's Disorder (TD)
NCT02864589 · Tourette's Disorder, Persistent (Chronic) Motor or Vocal Tic Disorder
NCT01585207 · Tourette's Disorder
NCT01727713 · Tourette's Disorder, Tic Disorder
Inha University Hospital
Incheon
Chonbuk National University Hospital
Jeonju
Seoul National University Hospital
Seoul
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions